Abiopharma

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of Americas Most Successful Small-Cap Companies

CoyaTherapeutics - Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Halozyme - Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab withENHANZE®

(90% Positive) GRI BIO, INC. (GRI) Provides Update on modulators for Idiopathic Pulmonary Fibrosis

Ecolab Inc. - Ecolab Earns Double ‘A’ Rating from CDP for Leadership in Water and Climate Performance

(90% Positive) MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Provides Update on opportunities for inflammat

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621

Akanda Corp (AKAN) Files Form 6-K

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

XWELL Reaffirms Commitment to Biosecurity, Appoints Former CDC Senior Advisor

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference